These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24673857)

  • 1. Successful treatment of transient osteoporosis with intravenous zoledronate: a case report.
    Maslin D; Karanth M; Bhagat S; Guirguis R
    Int J Rheum Dis; 2014 Sep; 17(7):816-7. PubMed ID: 24673857
    [No Abstract]   [Full Text] [Related]  

  • 2. A once-yearly IV bisphosphonate for osteoporosis.
    Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
    [No Abstract]   [Full Text] [Related]  

  • 3. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
    Hagino H; Hashimoto J; Okano T; Katagiri H
    Clin Calcium; 2008 Aug; 18(8):1176-82. PubMed ID: 18677057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consultation corner. Bone loss drug gives users a break.
    Bellantoni M
    Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
    [No Abstract]   [Full Text] [Related]  

  • 5. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
    Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
    [No Abstract]   [Full Text] [Related]  

  • 6. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of zoledronic acid on bone density and markers of bone turnover in a community clinic.
    Lim R; Zailskas S; Goldsby TU; Lukens C; Muravev R; Dulipsingh L
    Conn Med; 2013; 77(6):357-9. PubMed ID: 23923255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
    Miyakoshi N
    Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient migratory osteoporosis: rapid response to pamidronate treatment.
    Carty S; Herdman G; Williams F; Srinivasan U
    J Clin Rheumatol; 2007 Jun; 13(3):138-9. PubMed ID: 17551379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
    J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravenous neridronate in pediatric bone loss associated to Crohn's disease: a case report.
    Diamanti A; Noto C; Basso MS; Papadatou B; Bracci F; Castro M
    Clin Exp Rheumatol; 2009; 27(1):165. PubMed ID: 19327248
    [No Abstract]   [Full Text] [Related]  

  • 13. New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life.
    Duke Med Health News; 2007 Dec; 13(12):8. PubMed ID: 18286732
    [No Abstract]   [Full Text] [Related]  

  • 14. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
    Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I
    Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
    Konsta M; Bournia VK; Dania V; Iliopoulos A
    J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
    [No Abstract]   [Full Text] [Related]  

  • 16. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis.
    Mattheos N; Caldwell P; Petcu EB; Ivanovski S; Reher P
    J Can Dent Assoc; 2013; 79():d2. PubMed ID: 23763726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment goals of osteoporosis].
    Hosoi T
    Clin Calcium; 2014 Mar; 24(3):385-9. PubMed ID: 24576935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncommon transient osteoporosis of pregnancy at multiple sites associated with cytomegalovirus infection: is there a link?
    Rozenbaum M; Boulman N; Rimar D; Kaly L; Rosner I; Slobodin G
    Isr Med Assoc J; 2011 Nov; 13(11):709-11. PubMed ID: 22279710
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
    Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
    J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
    [No Abstract]   [Full Text] [Related]  

  • 20. Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.
    Tu CW; Huang KF; Hsu HT; Li HY; Yang SS; Chen YC
    J Surg Res; 2014 Nov; 192(1):112-6. PubMed ID: 24948545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.